/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.
/PRNewswire/ At the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts.
XPOVIO (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in tripleclass refractory R/R MM. XPOVIO is the first of a new class of SINE medicines to be made available to Australian patients with penta-refractory R/R MM on the Pharmaceutical Benefits Scheme (PBS). SHANGHAI and HONG KONG, Sept. 1, 2022 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that XPOVIO (selinexor) in combination with dexamethasone (Xd) has been PBS Listed for the treatment of adult patients with R/R MM who have received at least four prior lines of therapy and whose disease is refra
/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.
ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 monotherapy in patients with advanced tumors and hematologic malignancies. SHANGHAI and HONG KONG, Aug. 16, 2022 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announcedthat the first patient has been dosed in the Phase I ATRIUM trial to evaluate ATG-018 as a monotherapy in patients with advanced solid tumors and hematologic malignancies in Australia. The ATRIUM trial is a Phase I multi-center, open-label, dose f